Medical societies could petition for new drug indications under Senate reform proposal.
This article was originally published in The Tan Sheet
Executive Summary
MEDICAL SOCIETIES COULD PETITION FDA FOR APPROVAL OF NEW INDICATIONS that are clinically accepted under the Senate Labor & Human Resources Committee's FDA reform concept paper. A medical society would be required to support a supplemental NDA with documentation showing that "(1) the new use has existed in clinical practice for at least five years; (2) the new use is common among clinicians experienced in the field; or (3) the new use represents standard medical practice," according to the committee document.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning